Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma
Biology of Blood and Marrow Transplantation (2018)
  • Ryan D. Cassaday, University of Washington
  • Oliver W. Press, University of Washington
  • John M. Pagel, Cancer Institute
  • Joseph G. Rajendran, University of Washington
  • Ted Alan Gooley, Fred Hutchinson Cancer Research Center
  • Darrell R. Fisher, Pacific Northwest National Laboratory
  • Robert S. Miyaoka, University of Washington
  • David G. Maloney, Fred Hutchinson Cancer Research Center
  • Stephen D. Smith, Fred Hutchinson Cancer Research Center
  • Brian G. Till, Fred Hutchinson Cancer Research Center
  • Daniel B. Martin, University of Washington
  • Leona A. Holmberg, Fred Hutchinson Cancer Research Center
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • Ajay K. Gopal, University of Washington
Link
Disciplines
Publication Date
March 1, 2018
DOI
10.1016/j.bbmt.2017.12.227
Citation Information
Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, et al.. "Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma" Biology of Blood and Marrow Transplantation Vol. 24 Iss. 3 (2018)
Available at: http://works.bepress.com/john-pagel/3/